nvo stock - Search News

Novo Nordisk's stock rises

Novo Nordisk Stock Slides Before Q4 Earnings: Analysts Still See 68% Upside

Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% YTD. Analysts see 68% upside.

The Motley Fool on MSN · 1d

Why Novo Nordisk Stock Is Soaring Today

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but gained as much as 5.8% earlier in the day. The leg up comes as the S&P 500 ( ^GSPC 0.26%) gained 0.2%, and the Nasdaq Composite ( ^IXIC 0.02%) lost 0.1% on the day.

Seeking Alpha · 1d

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO stock from hold to buy.

Novo Nordisk says it's not immune to potential Trump tariffs

Business Insider · 1d

Novo Nordisk’s (NVO) CEO Is Not Worried About Government Price Negotiations

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes

Bloomberg on MSN · 1d

Novo Nordisk Is Prepared for Trump’s Tariff Threat, CEO Says

Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive said, as tensions simmer between Copenhagen and Washington.

Reuters · 1d

Novo Nordisk says it's not immune to potential Trump tariffs, but business is well-positioned

Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, its chief executive said on Wednesday, but it is confident its business is well-positioned.

Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Zacks.com on MSN1d

NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Yahoo Finance9d

How to Play NVO Stock After New Drug's Success in Obesity Study

Additionally, several other factors have significantly contributed to the decline of the stock recently. Last month, Novo Nordisk’s shares plunged after it failed to meet the efficacy guidance ...

18hon MSN

Wegovy maker Novo Nordisk says surging growth driving emissions higher

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Novo Nordisk's stock rises

Novo Nordisk says it's not immune to potential Trump tariffs

Related topics